These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 24256157)

  • 41. User views on supervised methadone consumption.
    Stone E; Fletcher K
    Addict Biol; 2003 Mar; 8(1):45-8. PubMed ID: 12745415
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Methadone and Buprenorphine for Opioid Dependence During Pregnancy: A Retrospective Cohort Study: Re: Meyer et al.
    McCarthy JJ
    J Addict Med; 2016; 10(2):133-4. PubMed ID: 26985649
    [No Abstract]   [Full Text] [Related]  

  • 43. Methadone Medical Maintenance: An Early 21st-Century Perspective.
    Novick DM; Salsitz EA; Joseph H; Kreek MJ
    J Addict Dis; 2015; 34(2-3):226-37. PubMed ID: 26110221
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chronic pain, craving, and illicit opioid use among patients receiving opioid agonist therapy.
    Tsui JI; Lira MC; Cheng DM; Winter MR; Alford DP; Liebschutz JM; Edwards RR; Samet JH
    Drug Alcohol Depend; 2016 Sep; 166():26-31. PubMed ID: 27422763
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intervention stigma: How medication-assisted treatment marginalizes patients and providers.
    Madden EF
    Soc Sci Med; 2019 Jul; 232():324-331. PubMed ID: 31125801
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Switching opioid-dependent patients in substitution treatment from racemic methadone, levomethadone and buprenorphine to slow-release oral morphine: Analysis of the switching process in routine care.
    Baschirotto C; Lehmann K; Kuhn S; Reimer J; Verthein U
    J Pharmacol Sci; 2020 Sep; 144(1):9-15. PubMed ID: 32586692
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Update on pharmacotherapy for treatment of opioid use disorder.
    Ayanga D; Shorter D; Kosten TR
    Expert Opin Pharmacother; 2016 Dec; 17(17):2307-2318. PubMed ID: 27734745
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Primary healthcare-based integrated care with opioid agonist treatment: First experience from Ukraine.
    Morozova O; Dvoriak S; Pykalo I; Altice FL
    Drug Alcohol Depend; 2017 Apr; 173():132-138. PubMed ID: 28242537
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The prescribing of methadone and other opioids to addicts: national survey of GPs in England and Wales.
    Strang J; Sheridan J; Hunt C; Kerr B; Gerada C; Pringle M
    Br J Gen Pract; 2005 Jun; 55(515):444-51. PubMed ID: 15970068
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Stigma from the Viewpoint of the Patient.
    Woods JS; Joseph H
    J Addict Dis; 2015; 34(2-3):238-47. PubMed ID: 26076048
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The real-world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine.
    Farnum SO; Makarenko I; Madden L; Mazhnaya A; Marcus R; Prokhorova T; Bojko MJ; Rozanova J; Dvoriak S; Islam Z; Altice FL
    Addiction; 2021 Jan; 116(1):83-93. PubMed ID: 32428276
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Just call it "treatment".
    Friedmann PD; Schwartz RP
    Addict Sci Clin Pract; 2012 Jun; 7(1):10. PubMed ID: 23186149
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use and misuse of opioid replacement therapies: a Queensland study.
    Smirnov A; Kemp R
    Subst Use Misuse; 2012 Jan; 47(1):78-85. PubMed ID: 22216993
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Commentary on Cousins et al. (2016): Accumulating evidence on risk of mortality on and off opioid substitution treatment.
    Hickman M; Macleod J; Degenhardt L
    Addiction; 2016 Jan; 111(1):83-4. PubMed ID: 26669528
    [No Abstract]   [Full Text] [Related]  

  • 55. A randomized controlled trial of buprenorphine for probationers and parolees: Bridging the gap into treatment.
    Gordon MS; Vocci FJ; Taxman F; Fishman M; Sharma B; Blue TR; O'Grady KE
    Contemp Clin Trials; 2019 Apr; 79():21-27. PubMed ID: 30797042
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder.
    Haffajee RL; Andraka-Christou B; Attermann J; Cupito A; Buche J; Beck AJ
    Subst Abuse Treat Prev Policy; 2020 Sep; 15(1):69. PubMed ID: 32928272
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A systematic review of sex differences in treatment outcomes among people with opioid use disorder receiving buprenorphine maintenance versus other treatment conditions.
    Ling S; Mangaoil R; Cleverley K; Sproule B; Puts M
    Drug Alcohol Depend; 2019 Apr; 197():168-182. PubMed ID: 30831429
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine.
    Chisolm MS; Fitzsimons H; Leoutsakos JM; Acquavita SP; Heil SH; Wilson-Murphy M; Tuten M; Kaltenbach K; Martin PR; Winklbaur B; Jansson LM; Jones HE
    Nicotine Tob Res; 2013 Jul; 15(7):1297-304. PubMed ID: 23288871
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
    Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
    Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.
    Socias ME; Ahamad K; Le Foll B; Lim R; Bruneau J; Fischer B; Wild TC; Wood E; Jutras-Aswad D
    Contemp Clin Trials; 2018 Jun; 69():21-27. PubMed ID: 29627621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.